The U.S. FDA has granted orphan drug designation to HCB101, an investigational immunotherapy, for the treatment of gastric cancer.
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...
Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in first-line gastric or gastroesophageal cancer. The AK104-302 trial ...
HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase III clinical study (AK112-306/HARMONi-6 study) ...
Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial. This is an ASCO Meeting ...
MedPage Today on MSN
For Your Patients: A Look at Promising New Treatments for Gastric Cancer
Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...
These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population. In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results